FDA gives Sun Pharma go-ahead to manufacture generic version of cancer drug Gleevec

The FDA has given Sun Pharmaceutical Industries approval to manufacture and market 100-milligram and 400-milligram tablets of its generic version of the expensive cancer drug Gleevec. The drug was originally developed and marketed by Swiss drugmaker Novartis ($NVS) in 2003 to treat chronic myeloid leukemia, a usually fatal blood cancer. In an earnings call, Sun management said it has shifted its Gleevec product filings from its troubled Halol facility, which has been under the FDA microscope for a number of violations. The regulatory agency said Sun can begin marketing the generic Feb. 1. It's expected other generic drugmakers in India, such as Dr. Reddy's ($RDY), will begin making a Gleevec generic by the second half of 2016. More from FiercePharmaAsia | Economic Times story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.